Association between ocular findings and preventive therapy with onset of central nervous system involvement in patients with primary vitreoretinal lymphoma

  • Noriyasu Hashida
  • Kei Nakai
  • Norimitsu Saitoh
  • Kohji Nishida
Oncology

Abstract

Purpose

To investigate if the site of ocular lesions and prophylactic treatment in patients with primary vitreoretinal lymphoma (PVRL) are associated with the time to onset of central nervous system (CNS) involvement.

Methods

We retrospectively studied 26 patients (seven men, 19 women; mean age, 67.0 ± 11.1 years) with a diagnosis of PVRL at our hospital between January 2001 and October 2011 and a minimum 2-year follow-up after treatment. We classified the PVRL lesions as: (1) the vitreous opacity type, vitreous opacity of 2+ or higher without retinal lesions, (2) the retina type, vitreous opacity of 1+ or less with retinal lesions only, or (3) the concomitant type, with both. We also evaluated whether prophylactic treatment of systemic chemotherapy such as high-dose methotrexate (HD-MTX) and intrathecal MTX (IT-MTX), or topical ocular treatments such as intravitreal injections of MTX and rituximab, inhibited the onset of CNS involvement in patients with PVRL without cerebral involvement.

Results

During a mean follow-up of 44.0 ± 18.7 months, CNS involvement began in 14 patients (53.8 %), i.e., three (60 %) of five patients with retina-type lesions, five (41.7 %) of 12 patients with vitreous opacity-type lesions, and six (66.7 %) of nine patients with concomitant-type lesions. There was no significant (P = 0.496) association between the site of the ocular lesions and the onset of brain lesions. In addition, CNS involvement occurred in eight of 11 patients receiving CNS prophylactic chemotherapy and six of 15 patients receiving no prophylaxis; the difference between the two did not reach significance (P = 0.131). The time to onset of cerebral involvement in the CNS prophylactic chemotherapy group (42.8 ± 13.8 months) was significantly (P = 0.0005) longer than in the group that did not receive prophylaxis (10.2 ± 2.0 months). Preventive systemic chemotherapy, especially HD-MTX, significantly prolonged the time to the onset of brain lesions compared to IT-MTX and local ocular therapy.

Conclusions

While prophylactic systemic chemotherapy did not inhibit the onset of CNS involvement in most of patients with PVRL, it significantly prolonged the time to cerebral involvement.

Keywords

Primary vitreoretinal lymphoma Prophylactic treatment CNS involvement Systemic chemotherapy Methotrexate 

Notes

Acknowledgments

We would like to thank Dr. Nobuyuki Ohguro for contribution in management of the patients and his assistance towards data collection at the start of the study.

Conflict of interest

The authors have no proprietary or commercial interest in any material discussed in this article.

Financial support

Supported in part by grants-in-aid for scientific research from the Japanese Ministry of Education, Culture, Sports, Science and Technology (C-23592604).

Study registration

This study was registered with the University Hospital Medical information Network Clinical Trials Registry (registration number, UMIN000005604; registration date, 2007/01/01; beginning date of trial, 2008/06/01; available at: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000006623&language=E).

References

  1. 1.
    Coupland SE, Chan CC, Smith J (2009) Pathophysiology of retinal lymphoma. Ocul Immunol Inflamm 17:227–237PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Schabet M (1999) Epidemiology of primary CNS lymphoma. J Neurooncol 43:199–201PubMedCrossRefGoogle Scholar
  3. 3.
    Coupland SE, Heimann H, Bechrakis NE (2004) Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features. Graefes Arch Clin Exp Ophthalmol 242:901–913PubMedCrossRefGoogle Scholar
  4. 4.
    Commins DL (2006) Pathology of primary central nervous system lymphoma. Neurosurg Focus 21:E2PubMedCrossRefGoogle Scholar
  5. 5.
    Hochberg FH, Baehring JM, Hochberg EP (2007) Primary CNS lymphoma. Nat Clin Pract Neurol 3:24–35PubMedCrossRefGoogle Scholar
  6. 6.
    Peterson K, Gordon KB, Heinemann MH, DeAngelis LM (1993) The clinical spectrum of ocular lymphoma. Cancer 72:843–849PubMedCrossRefGoogle Scholar
  7. 7.
    Cassoux N, Merle-Beral H, Leblond V, Bodaghi B, Miléa D, Gerber S, Fardeau C, Reux I, Xuan KH, Chan CC, LeHoang P (2000) Ocular and central nervous system lymphoma: clinical features and diagnosis. Ocul Immunol Inflamm 8:243–250PubMedCrossRefGoogle Scholar
  8. 8.
    Chan CC, Rubenstein JL, Coupland SE, Davis JL, Harbour JW, Johnston PB, Cassoux N, Touitou V, Smith JR, Batchelor TT, Pulido JS (2011) Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist 16:1589–1599PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Chan CC, Sen HN (2013) Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma. Discov Med 15:93–100PubMedCentralPubMedGoogle Scholar
  10. 10.
    Sierra Del Rio M, Rousseau A, Soussain C, Ricard D, Hoang-Xuan K (2009) Primary CNS lymphoma in immunocompetent patients. Oncologist 14:526–539PubMedCrossRefGoogle Scholar
  11. 11.
    Fishburne BC, Wilson DJ, Rosenbaum JT, Neuwelt EA (1997) Intravitreal methotrexate as an adjunctive treatment of ocular lymphoma. Arch Ophthalmol 115:1152–1156PubMedCrossRefGoogle Scholar
  12. 12.
    de Smet MD, Vancs VS, Kohler D, Solomon D, Chan CC (1999) Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma. Br J Ophthalmol 83:448–451PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Smith JR, Rosenbaum JT, Wilson DJ, Doolittle ND, Siegal T, Neuwelt EA, Pe'er J (2002) Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 109:1709–1716PubMedCrossRefGoogle Scholar
  14. 14.
    Kitzmann AS, Pulido JS, Mohney BG, Baratz KH, Grube T, Marler RJ, Donaldson MJ, O'Neill BP, Johnston PB, Johnson KM, Dixon LE, Salomao DR, Cameron JD (2007) Intraocular use of rituximab. Eye (Lond) 21:1524–1527CrossRefGoogle Scholar
  15. 15.
    Ohguro N, Hashida N, Tano Y (2008) Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma. Arch Ophthalmol 126:1002–1003PubMedCrossRefGoogle Scholar
  16. 16.
    Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE (2006) Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24:4570–4574PubMedCrossRefGoogle Scholar
  17. 17.
    Hill QA, Owen RG (2006) CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev 20:319–332PubMedCrossRefGoogle Scholar
  18. 18.
    Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y (2002) Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-Hodgkin lymphoma. Cancer 95:576–580PubMedCrossRefGoogle Scholar
  19. 19.
    Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leithäuser M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Weller M (2010) High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 11:1036–1047PubMedCrossRefGoogle Scholar
  20. 20.
    Soussain C, Choquet S, Fourme E, Delgadillo D, Bouabdallah K, Ghesquières H, Damaj G, Dupriez B, Vargaftig J, Gonzalez A, Houillier C, Taillandier L, Hoang-Xuan K, Leblond V (2012) Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: A retrospective study of 79 cases. Haematologica 97:1751–1756PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Abrey LE, DeAngelis LM, Yahalom J (1998) Long-term survival in primary CNS lymphoma. J Clin Oncol 16:859–863PubMedGoogle Scholar
  22. 22.
    Kiewe P, Fischer L, Martus P, Thiel E, Korfel A (2010) Meningeal dissemination in primary CNS lymphoma: diagnosis, treatment, and survival in a large monocenter cohort. Neuro Oncol 12:409–417PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Freeman LN, Schachat AP, Knox DL, Michels RG, Green WR (1987) Clinical features, laboratory investigations, and survival in ocular reticulum cell sarcoma. Ophthalmology 94:1631–1639PubMedCrossRefGoogle Scholar
  24. 24.
    Char DH, Ljung BM, Miller T, Phillips T (1988) Primary intraocular lymphoma (ocular reticulum cell sarcoma) diagnosis and management. Ophthalmology 95:625–630PubMedCrossRefGoogle Scholar
  25. 25.
    Siegel MJ, Dalton J, Friedman AH, Strauchen J, Watson C (1989) Ten-year experience with primary ocular 'reticulum cell sarcoma' (large cell non-Hodgkin's lymphoma). Br J Ophthalmol 73:342–346PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Buggage RR, Chan CC, Nussenblatt RB (2001) Ocular manifestations of central nervous system lymphoma. Curr Opin Oncol 13:137–142PubMedCrossRefGoogle Scholar
  27. 27.
    Ferreri AJ, Blay JY, Reni M, Pasini F, Gubkin A, Tirelli U, Calderoni A, Zucca E, Cortelazzo S, Chassagne C, Tinguely M, Borisch B, Berger F, Ponzoni M, Cavalli F, International Extranodal Lymphoma Study Group (IELSG) (2002) Relevance of intraocular involvement in the management of primary central nervous system lymphomas. Ann Oncol 13:531–538PubMedCrossRefGoogle Scholar
  28. 28.
    Jahnke K, Korfel A, Komm J, Bechrakis NE, Stein H, Thiel E, Coupland SE (2006) Intraocular lymphoma 2000–2005: results of a retrospective multicentre trial. Graefes Arch Clin Exp Ophthalmol 244:663–669PubMedCrossRefGoogle Scholar
  29. 29.
    Batchelor TT, Kolak G, Ciordia R, Foster CS, Henson JW (2003) High-dose methotrexate for intraocular lymphoma. Clin Cancer Res 9:711–715PubMedGoogle Scholar
  30. 30.
    Vosganian GS, Boisot S, Hartmann KI, Freeman WR, Sharpe RW, Tripuraneni P, Saven A (2011) Primary intraocular lymphoma: a review. J Neurooncol 105:127–134PubMedCrossRefGoogle Scholar
  31. 31.
    Chan CC, Wallace DJ (2004) Intraocular lymphoma: update on diagnosis and management. Cancer Control 11:285–295PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Noriyasu Hashida
    • 1
  • Kei Nakai
    • 1
  • Norimitsu Saitoh
    • 2
  • Kohji Nishida
    • 1
  1. 1.Department of OphthalmologyOsaka University Graduate School of MedicineSuitaJapan
  2. 2.Department of Hematology and OncologyOsaka University Graduate School of MedicineOsakaJapan

Personalised recommendations